NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript

April 30, 2026 02:41:46 pm

Source: SeekingAlpha

2026-04-30 14:41:46 ET

NovoCure Limited (NVCR) Q1 2026 Earnings Call April 30, 2026 8:00 AM EDT

Company Participants

Adam Daney - Head of Investor Relations
William Doyle - Executive Chairman
Frank Leonard - Chief Executive Officer
Christoph Brackmann - Chief Financial Officer
Uri Weinberg - Chief Innovation Officer & Chief Medical Officer
...

Read the full article on Seeking Alpha

For further details see:

NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript

NovoCure Limited

NASDAQ: NVCR

NVCR Trading

28.92% G/L:

$15.20 Last:

3,202,896 Volume:

$13.36 Open:

NVCR Latest News

April 30, 2026 07:00:00 am

Novocure Reports First Quarter 2026 Financial Results

April 01, 2026 07:00:00 am

Novocure to Report First Quarter 2026 Financial Results

March 26, 2026 11:52:57 pm

Novocure Stock Surges on Promising Pancreatic Cancer Trial Results

March 26, 2026 07:00:00 am

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

NVCR Stock Data

Market Cap $1,170,211,701

Float 105,800,576

Insiders Ownership 0.07%

Institutions 77

Short Percent N/A

Industry Medical Equipment & Supplies

Sector Healthcare

Website https://www.novocure.com

Country JE

City St. Helier